Logo image of RARE

ULTRAGENYX PHARMACEUTICAL IN (RARE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RARE - US90400D1081 - Common Stock

23.21 USD
-0.99 (-4.09%)
Last: 1/8/2026, 4:59:08 PM
23.21 USD
0 (0%)
After Hours: 1/8/2026, 4:59:08 PM
Fundamental Rating

2

RARE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. Both the profitability and financial health of RARE have multiple concerns. RARE is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RARE has reported negative net income.
RARE had a negative operating cash flow in the past year.
In the past 5 years RARE always reported negative net income.
RARE had a negative operating cash flow in each of the past 5 years.
RARE Yearly Net Income VS EBIT VS OCF VS FCFRARE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

With a Return On Assets value of -48.71%, RARE perfoms like the industry average, outperforming 51.89% of the companies in the same industry.
With a Return On Equity value of -6330.70%, RARE is not doing good in the industry: 81.32% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -48.71%
ROE -6330.7%
ROIC N/A
ROA(3y)-41.44%
ROA(5y)-32.95%
ROE(3y)-214.63%
ROE(5y)-141.85%
ROIC(3y)N/A
ROIC(5y)N/A
RARE Yearly ROA, ROE, ROICRARE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

RARE has a better Gross Margin (84.69%) than 87.36% of its industry peers.
In the last couple of years the Gross Margin of RARE has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for RARE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.69%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.3%
GM growth 5Y-1.12%
RARE Yearly Profit, Operating, Gross MarginsRARE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K -200K

More info and screens

1

2. Health

2.1 Basic Checks

RARE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RARE has more shares outstanding
The number of shares outstanding for RARE has been increased compared to 5 years ago.
RARE has a better debt/assets ratio than last year.
RARE Yearly Shares OutstandingRARE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
RARE Yearly Total Debt VS Total AssetsRARE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

RARE has an Altman-Z score of -4.67. This is a bad value and indicates that RARE is not financially healthy and even has some risk of bankruptcy.
RARE has a worse Altman-Z score (-4.67) than 61.32% of its industry peers.
A Debt/Equity ratio of 83.39 is on the high side and indicates that RARE has dependencies on debt financing.
The Debt to Equity ratio of RARE (83.39) is worse than 81.51% of its industry peers.
Industry RankSector Rank
Debt/Equity 83.39
Debt/FCF N/A
Altman-Z -4.67
ROIC/WACCN/A
WACC8.24%
RARE Yearly LT Debt VS Equity VS FCFRARE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

A Current Ratio of 1.89 indicates that RARE should not have too much problems paying its short term obligations.
With a Current ratio value of 1.89, RARE is not doing good in the industry: 77.17% of the companies in the same industry are doing better.
A Quick Ratio of 1.74 indicates that RARE should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.74, RARE is doing worse than 77.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.74
RARE Yearly Current Assets VS Current LiabilitesRARE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

7

3. Growth

3.1 Past

RARE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.19%, which is quite good.
The Revenue has grown by 20.63% in the past year. This is a very strong growth!
RARE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 40.13% yearly.
EPS 1Y (TTM)8.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.29%
Revenue 1Y (TTM)20.63%
Revenue growth 3Y16.82%
Revenue growth 5Y40.13%
Sales Q2Q%14.65%

3.2 Future

RARE is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.40% yearly.
Based on estimates for the next years, RARE will show a very strong growth in Revenue. The Revenue will grow by 31.78% on average per year.
EPS Next Y7.44%
EPS Next 2Y15.7%
EPS Next 3Y20.32%
EPS Next 5Y24.4%
Revenue Next Year19.49%
Revenue Next 2Y20.05%
Revenue Next 3Y29.3%
Revenue Next 5Y31.78%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RARE Yearly Revenue VS EstimatesRARE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
RARE Yearly EPS VS EstimatesRARE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 -10 15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RARE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RARE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RARE Price Earnings VS Forward Price EarningsRARE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RARE Per share dataRARE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

RARE's earnings are expected to grow with 20.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.7%
EPS Next 3Y20.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RARE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ULTRAGENYX PHARMACEUTICAL IN

NASDAQ:RARE (1/8/2026, 4:59:08 PM)

After market: 23.21 0 (0%)

23.21

-0.99 (-4.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-11 2026-02-11/amc
Inst Owners103.06%
Inst Owner Change0%
Ins Owners3.24%
Ins Owner Change-0.67%
Market Cap2.24B
Revenue(TTM)630.60M
Net Income(TTM)-579.83M
Analysts85.19
Price Target83.74 (260.79%)
Short Float %9.34%
Short Ratio4.78
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.03%
Min EPS beat(2)-43.75%
Max EPS beat(2)11.68%
EPS beat(4)2
Avg EPS beat(4)-8.27%
Min EPS beat(4)-43.75%
Max EPS beat(4)11.68%
EPS beat(8)5
Avg EPS beat(8)-2.83%
EPS beat(12)6
Avg EPS beat(12)-4.05%
EPS beat(16)6
Avg EPS beat(16)-13.56%
Revenue beat(2)1
Avg Revenue beat(2)-2.46%
Min Revenue beat(2)-5.94%
Max Revenue beat(2)1.02%
Revenue beat(4)2
Avg Revenue beat(4)-1.49%
Min Revenue beat(4)-5.94%
Max Revenue beat(4)4.02%
Revenue beat(8)5
Avg Revenue beat(8)1.05%
Revenue beat(12)6
Avg Revenue beat(12)-1.01%
Revenue beat(16)7
Avg Revenue beat(16)-1.78%
PT rev (1m)0.44%
PT rev (3m)-2.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.55%
EPS NY rev (1m)0%
EPS NY rev (3m)-14.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.55
P/FCF N/A
P/OCF N/A
P/B 244.49
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.94
EYN/A
EPS(NY)-4.19
Fwd EYN/A
FCF(TTM)-4.83
FCFYN/A
OCF(TTM)-4.62
OCFYN/A
SpS6.54
BVpS0.09
TBVpS-2.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.71%
ROE -6330.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.69%
FCFM N/A
ROA(3y)-41.44%
ROA(5y)-32.95%
ROE(3y)-214.63%
ROE(5y)-141.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.3%
GM growth 5Y-1.12%
F-Score2
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 83.39
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 58.7%
Cap/Sales 3.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.74
Altman-Z -4.67
F-Score2
WACC8.24%
ROIC/WACCN/A
Cap/Depr(3y)346.02%
Cap/Depr(5y)389.65%
Cap/Sales(3y)18.19%
Cap/Sales(5y)18.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-29.29%
EPS Next Y7.44%
EPS Next 2Y15.7%
EPS Next 3Y20.32%
EPS Next 5Y24.4%
Revenue 1Y (TTM)20.63%
Revenue growth 3Y16.82%
Revenue growth 5Y40.13%
Sales Q2Q%14.65%
Revenue Next Year19.49%
Revenue Next 2Y20.05%
Revenue Next 3Y29.3%
Revenue Next 5Y31.78%
EBIT growth 1Y-1.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.02%
EBIT Next 3Y21.41%
EBIT Next 5YN/A
FCF growth 1Y15.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.39%
OCF growth 3YN/A
OCF growth 5YN/A

ULTRAGENYX PHARMACEUTICAL IN / RARE FAQ

What is the ChartMill fundamental rating of ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to RARE.


Can you provide the valuation status for ULTRAGENYX PHARMACEUTICAL IN?

ChartMill assigns a valuation rating of 1 / 10 to ULTRAGENYX PHARMACEUTICAL IN (RARE). This can be considered as Overvalued.


How profitable is ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?

ULTRAGENYX PHARMACEUTICAL IN (RARE) has a profitability rating of 1 / 10.


What is the financial health of ULTRAGENYX PHARMACEUTICAL IN (RARE) stock?

The financial health rating of ULTRAGENYX PHARMACEUTICAL IN (RARE) is 1 / 10.


Is the dividend of ULTRAGENYX PHARMACEUTICAL IN sustainable?

The dividend rating of ULTRAGENYX PHARMACEUTICAL IN (RARE) is 0 / 10 and the dividend payout ratio is 0%.